Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments

World J Gastroenterol. 2014 Jun 7;20(21):6448-56. doi: 10.3748/wjg.v20.i21.6448.

Abstract

Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC) comprises nearly 10% of gastric carcinoma cases worldwide. Recently, it was recognised to have unique clinicopathologic characteristics, including male predominance, lower rates of lymph node involvement, and better prognosis. EBVaGC is further characterised by abnormal hypermethylation of tumour suppressor gene promoter regions, causing down-regulation of their expression. In the present review, we critically discuss the role of EBV in gastric carcinogenesis, summarising the role of viral proteins and microRNAs with respect to aberrant methylation in EBVaGC. Given the role of epigenetic dysregulation in tumourigenesis, epigenetic modifiers may represent a novel therapeutic strategy.

Keywords: Aberrant DNA methylation; Epigenetic dysregulation; Epigenetic therapies; Epstein-Barr virus; Gastric carcinoma.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • CpG Islands
  • DNA Methylation
  • Epigenesis, Genetic*
  • Epstein-Barr Virus Infections / complications*
  • Gene Expression Regulation, Neoplastic*
  • Genes, Tumor Suppressor
  • Herpesvirus 4, Human*
  • Humans
  • MicroRNAs / metabolism
  • Prognosis
  • Stomach Neoplasms / complications
  • Stomach Neoplasms / genetics*
  • Stomach Neoplasms / virology*
  • Viral Proteins / metabolism

Substances

  • MicroRNAs
  • Viral Proteins